Overview Performance Dividends Fundamentals Peer Group Correlations Pair Trades Institutions Insider Forecasts Options

DHR - Danaher - Stock Price & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US2358511028

Biotechnology, Diagnostics, Life Sciences

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia. Web URL: https://www.danaher.com

Drawdown (Underwater) Chart

Overall Trend and Yearly Seasonality

DHR Stock Overview

Market Cap in USD	192,845m
Sector	Healthcare
Industry	Diagnostics & Research
GiC SubIndustry	Health Care Equipment
TER	0.00%
IPO / Inception	1979-01-05

DHR Stock Ratings

Growth 5y	70.1
Fundamental	28.1
Dividend	59.4
Rel. Performance vs Sector	0.07
Analysts	4.29/5
Fair Price Momentum	278.97 USD
Fair Price DCF	176.24 USD

DHR Dividends

Dividend Yield 12m	0.39%
Yield on Cost 5y	0.86%
Dividends CAGR 5y	10.40%
Payout Consistency	95.1%

DHR Growth Ratios

Growth 12m	22.07%
Growth Correlation 12m	88%
Growth Correlation 3m	65%
CAGR 5y	17.33%
CAGR/Mean DD 5y	1.37
Sharpe Ratio 12m	0.73
Alpha vs SP500 12m	0.03
Beta vs SP500 5y weekly	0.81
ValueRay RSI	62.51
Volatility GJR Garch 1y	21.72%
Price / SMA 50	3.57%
Price / SMA 200	9.37%
Current Volume	1999.4k
Average Volume 20d	1999.6k

External Links for DHR Stock

News
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle

What is the price of DHR stocks?
As of September 12, 2024, the stock is trading at USD 271.98 with a total of 1,999,356 shares traded.
Over the past week, the price has changed by +2.83%, over one month by +1.79%, over three months by +4.22% and over the past year by +21.57%.

What are the forecast for DHR stock price target?
According to ValueRays Forecast Model, DHR Danaher will be worth about 307 in September 2025. The stock is currently trading at 271.98. This means that the stock has a potential upside of +12.89%.

Issuer	Forecast	Upside
Wallstreet Target Price	255.8	-5.93
Analysts Target Price	246.8	-9.25
ValueRay Target Price	307	12.9

The Evolution and Current Standings of Danaher Corporation

History

Founded in 1969 by Steven Rales and Mitchell Rales, Danaher Corporation started off as a real estate investment trust. It was not long before the company pivoted towards manufacturing and the science and technology sector, embarking on a strategy of growth through acquisitions. This approach propelled Danaher from its modest beginnings into a global conglomerate.

Core Business

Danaher's core business today revolves around the design, manufacturing, and marketing of professional, medical, industrial, and commercial products and services. The enterprise is organized around three main segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. Each segment plays a critical role in research, healthcare, and industrial processes, contributing to advancements across various fields.

Side Business

Besides its pillars, Danaher engages in several side businesses, broadening its influence across the tech and innovation world. These include ventures in dental products, water quality solutions, and product identification. Notably, the company's strategy involves investing in businesses that complement its core operations, thereby strengthening its overall market position.

Current Market Status

As of the latest market analysis, Danaher Corporation (NYSE: DHR) has proven itself a formidable player within its industry. With a steady rise in stock prices and a strong presence in its sectors, Danaher continues to grow. The company's dedication to innovation, strategic acquisitions, and diversification of its product lineup and services keeps it at the forefront of emerging technologies and market trends.